Electra Therapeutics is developing SIRP-directed antibodies that utilize a unique mechanism of action to target the underlying pathology of cancer and immunological diseases. The company focuses on addressing critical unmet therapeutic needs by advancing its pipeline of novel treatments.
Funding
$118M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
WVFounders
Product
Problem
Many cancers and immunological diseases evade the body's natural defenses by manipulating the Signal Regulatory Protein (SIRP) pathway, preventing immune cells from recognizing and attacking diseased cells. Current treatment options often fail to fully address the underlying mechanisms that allow these diseases to progress.
Solution
Electra Therapeutics is developing a portfolio of Signal Regulatory Protein (SIRP)-directed antibodies designed to restore immune function and target the root causes of cancer and immunological disorders. Their antibodies employ a unique mechanism of action to disrupt the SIRP signaling pathway, enabling immune cells to effectively identify and eliminate diseased cells. By targeting this fundamental immune evasion strategy, Electra's therapies aim to provide more effective and durable responses for patients with critical unmet needs. The company is committed to rigorous scientific validation and advancing breakthrough treatments that can transform patient outcomes.
Target Audience
The primary target audience includes patients with cancer and immunological diseases who are not adequately responding to existing therapies, as well as the physicians who treat them.
Features
- SIRP-directed antibodies designed to modulate immune response
- Unique mechanism of action targeting the SIRP signaling pathway
- Potential application across a range of cancers and immunological diseases